Shorted

Cochlear (COH) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
13h ago

Does Cochlear (ASX:COH) Bring to the Healthcare Stocks Theme?

Highlights United States regulators cleared Cochlear's newest rechargeable Osia bone conduction sound processor. The redesigned processor drops disposable batteries entirely and adds direct streaming from consumer devices. Existing Osia implant recipients are expected to be able to upgrade without further surgery. Cochlear Limited (ASX:COH), the Sydney-based hearing implant maker, said its newest Osia Sound Processor has cleared United States regulatory review, a milestone for the [ASX 50] co...

Continue reading
Kalkine
Neutral
2d ago

What Could Make Cochlear (ASX:COH) a Key Name Among Healthcare Stocks?

Highlights Cochlear delivered underlying net profit at the upper end of its reset guidance range. The Nexa implant platform reached near-complete adoption across developed market unit volumes. Operating cash flow strengthened markedly even as reported margins absorbed discrete charges. Cochlear (ASX:COH), the Sydney-based hearing implant maker that supplies clinics across a wide spread of markets, emerged from the August reporting stretch with underlying profit at the upper end of its reset g...

Continue reading
Kalkine
Neutral
3d ago

Why Could Cochlear (ASX:COH) Matter for Value Stocks?

Highlights Discounted cash flow screens have flagged the implant maker as trading beneath estimated worth. A de-rating from earlier peaks has narrowed the premium the market once assigned it. Recurring services revenue continues to build behind the headline implant business. Cochlear (ASX:COH) is drawing a sharper market lens as sector conditions and company execution intersect across Australian equities. Cochlear (ASX:COH) has begun appearing on screens identifying Australian listed companie...

Continue reading
Kalkine
Neutral
3d ago

Can Healthcare Stocks Shift Around Cochlear (ASX:COH)?

Highlights Annual earnings from the hearing implant maker landed ahead of the subdued expectations the market had set. Services and sound processor upgrades continue to build a recurring revenue layer beneath implant sales. The shares edged higher as the result removed a cloud that had lingered over the device sector. The latest local-market debate around healthcare stocks has brought Cochlear (ASX:COH) back into view, with operating detail carrying more weight than broad sentiment. Cochlear ...

Continue reading
Kalkine
Positive
27 Aug

Can Cochlear (ASX:COH) Rally Further on Profit Jump?

Highlights Cochlear shares jumped after annual profit landed at the upper end of guidance issued earlier in the year. A compression in gross margin and softer implant revenue had earlier triggered a guidance downgrade that weighed on sentiment. Forward guidance points to steady constant currency revenue growth and a recovery in underlying profit over the coming year. Cochlear (ASX:COH) [ASX 50] shares jumped in trading after the hearing implant group reported an annual profit outcome that lan...

Continue reading
Kalkine
Neutral
25 Aug

What Is Keeping Cochlear (ASX:COH) on Track?

Highlights Underlying profit finished well below the prior year yet still landed at the upper end of revised guidance Sound processor upgrades and services revenue continue to smooth an inherently lumpy earnings profile Emerging market tender timing and currency translation remain the least predictable variables Cochlear firmed after a full-year result reported earlier this month landed at the upper end of the guidance range the company had revised during the year, extending a run of construc...

Continue reading
Kalkine
Neutral
21 Aug

What Is Changing for Cochlear (ASX:COH) in Healthcare Stocks?

Highlights Cochlear is being assessed through demand durability, product adoption and the quality of execution rather than short-term market direction. The healthcare stocks backdrop makes margin quality and research investment especially useful when separating company evidence from sector noise. Upcoming disclosures can clarify whether global execution is supporting or constraining the operating story around Cochlear. The Australian sharemarket is rewarding clarity rather than excitement, wh...

Continue reading
Kalkine
Neutral
20 Aug

Healthcare Stocks: What matters for Cochlear (ASX:COH) in ASX 300?

Highlights Rather than begin with the market narrative, this section starts inside Cochlear: recurring demand is tested against product mix before the ASX 300 context is considered. The central issue for Cochlear is whether regulatory pathway is reinforcing the signal coming from product mix. ASX 300 supplies context, but the coverage gives more weight to the companys operating sequence and sector-specific economics. A separate read of recurring demand helps distinguish durable business evidenc...

Continue reading
Kalkine
Neutral
19 Aug

Cochlear (ASX:COH) Sector Pulse: What Could Shape the Next Move on 19 August

Highlights Healthcare was the standout sector on 18 August: CSL rose sharply after its FY26 result, while Cochlear and Pro Medicus also drew strong market reactions. Cochlear (ASX:COH) is the primary company lens, while Pro Medicus (ASX:PME), ResMed (ASX:RMD), CSL (ASX:CSL) provide category context. The article focuses on earnings quality, product demand and healthcare growth durability without using directional investment recommendations. The central question for healthcare stocks is no long...

Continue reading
Kalkine
Neutral
19 Aug

What Is Shaping Cochlear (ASX:COH) Now?

Highlights Cochlear remains closely watched as implant innovation, clinical adoption and long-term hearing demand shapes its place within Australia's healthcare stocks landscape. Operational delivery, capital discipline and clear disclosure remain central to how the company's progress is assessed. Broader demand linked to ageing populations, improved diagnosis and demand for effective treatment pathways continues influencing the sector conversation. Australia's sharemarket is moving through a...

Continue reading
Kalkine
Neutral
18 Aug

Can Cochlear (ASX:COH) Keep Implant Demand Audible?

Highlights Implant demand visibility across global clinics is the central company-specific issue, with implant units providing the first operating check. Processor upgrades and clinic capacity show whether activity is translating into commercial quality and financial discipline. Procedure timing and changing health-system budgets remains the main constraint that could interrupt the operating sequence. A changing market backdrop is making operational clarity a central part of how Australian co...

Continue reading
Kalkine
Positive
18 Aug

What Will Cochlear (ASX:COH) Show About Upgrade Growth?

Highlights Implant upgrade growth across global clinics is the central company-specific issue, with implant demand providing the first operating check. Processor upgrades and clinic capacity show whether activity is translating into commercial quality and financial discipline. Procedure timing and uneven health-system budgets remains the main constraint that could interrupt the operating sequence. The current Australian reporting window is turning broad sector stories into company-by-company ...

Continue reading
Kalkine
Neutral
17 Aug

Cochlear (ASX:COH) Rebounds Into Its Reporting Week

Highlights A steep recovery from earlier lows has restored expectations before the device maker reports. Recurring services revenue provides a steadier counterweight to unit implant volumes. Emerging market reimbursement decisions remain the largest swing factor for unit growth. Cochlear (ASX:COH), the Sydney-based hearing implant manufacturer that supplies devices to markets across an extensive list of countries, has staged a pronounced recovery from the multi-year lows reached earlier in th...

Continue reading
Kalkine
Neutral
13 Aug

Cochlear (ASX:COH) Hearing Solution Innovation Progress Market Outlook

Highlights Hearing implant technology supporting medical device adoption International market expansion driving geographic diversification Product innovation pipeline strengthening competitive positioning Cochlear (ASX:COH) advances hearing solution innovation and international market expansion. The company continues developing implantable technologies addressing hearing loss across global markets. The broader market context can also be viewed through the S&P/ASX All Technology Index, w...

Continue reading
Kalkine
Neutral
11 Aug

Cochlear (ASX:COH) Hearing Solutions Advance Technology: What to Watch

Highlights Cochlear implant technology continues advancing hearing restoration capabilities Aging populations drive sustained hearing loss treatment demand Digital connectivity improves hearing device functionality and patient experience Cochlear Limited (ASX:COH) manufactures cochlear implant systems and hearing solutions for patients with hearing loss. The broader [ASX 200] remains an important benchmark for Australian market sentiment. The company addresses substantial patient population...

Continue reading
Kalkine
Neutral
10 Aug

Why Is Cochlear Limited (ASX:COH) Drawing Market Attention?

Highlights Cochlear Limited (ASX:COH) participates in healthcare sector advance through established leadership in hearing solutions and auditory devices Medical device company demonstrates market resilience through persistent hearing healthcare demand across global populations Ageing population demographics support long-term hearing healthcare market expansion driving sustained medical device demand Cochlear Limited (ASX:COH) advanced alongside broader healthcare sector gains in August suppor...

Continue reading
Kalkine
Neutral
4 Aug

Why Cochlear (ASX:COH) Remains In Focus Ahead Of FY26 Results

Highlights Cochlear's upcoming FY26 results remain a key focus following revised earnings expectations earlier this year. Product adoption, operational execution and cost management are expected to remain central themes during the upcoming earnings update. Healthcare innovation and global hearing implant demand continue shaping the long-term outlook for the sector. Australia's healthcare sector continues attracting investor attention as companies balance innovation with evolving operating cond...

Continue reading